Cart 0 Product Products (empty)
No products
To be determined Shipping
0,00 € Total
Prices are tax excluded
Product successfully added to your shopping cart
Quantity
Total
There are 0 items in your cart. There is 1 item in your cart.
Total products (tax excl.)
Total shipping (tax excl.) To be determined
Total (tax excl.)
Data sheet of SERPINE1 monoclonal antibody, clone MA14D5
| Brand | Abnova |
| Product type | Primary antibodies |
| Reactivity | Human |
| Host species | Mouse |
| Applications | ELISA |
More info about SERPINE1 monoclonal antibody, clone MA14D5
| Brand: | Abnova |
| Reference: | MAB3803 |
| Product name: | SERPINE1 monoclonal antibody, clone MA14D5 |
| Product description: | Mouse monoclonal antibody raised against recombinant SERPINE1. |
| Clone: | MA14D5 |
| Isotype: | IgG |
| Gene id: | 5054 |
| Gene name: | SERPINE1 |
| Gene alias: | PAI|PAI-1|PAI1|PLANH1 |
| Gene description: | serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 |
| Immunogen: | Recombinant protein corresponding to human SERPINE1. |
| Form: | Liquid |
| Recommend dilutions: | The optimal working dilution should be determined by the end user. |
| Storage buffer: | In 100 mM HEPES, 100 mM NaCl, 1 mM EDTA, pH 7.4 |
| Storage instruction: | Store at -80°C. Aliquot to avoid repeated freezing and thawing. |
| Product type: | Primary antibodies |
| Host species: | Mouse |
| Antigen species / target species: | Human |
| Specificity: | This mouse monoclonal antibody is specific to complexed forms of human plasminogen activator inhibitor-1 (PAI-1). This antibody exhibits neoantigenic properties that allow for binding with any complexed form of PAI-1. |
| Reactivity: | Human |
| Applications: | ELISA |
| Shipping condition: | Dry Ice |
| Publications: | Characterization of common neoantigenic epitopes generated in plasminogen activator inhibitor-1 after cleavage of the reactive center loop or after complex formation with various serine proteinases.Debrock S, Declerck PJ. FEBS Lett. 1995 Dec 4;376(3):243-6. |